Chris Slavinsky
Corporate Officer/Principal bei TAKEDA PHARMACEUTICAL COMPANY LIMITED
Profil
Chris Slavinsky is currently the VP-External Innovation & Head-Gastroenterology at Takeda Pharmaceutical Co., Ltd.
Prior to this, he held positions as the Director at Phathom Pharmaceuticals, Inc., Director at ARTham Therapeutics, Inc., General Counsel & Head-Business Development at Prometheus Biosciences, Inc., and General Counsel at Pharmacosmos Therapeutics Inc. He also served as the Chief Legal & Business Officer at Coherus BioSciences, Inc. from 2022 to 2023.
Mr. Slavinsky has a graduate degree from Thomas Jefferson University, an undergraduate degree from Stony Brook University, and a graduate degree from Washington University School of Law.
Aktive Positionen von Chris Slavinsky
| Unternehmen | Position | Beginn |
|---|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Chris Slavinsky
| Unternehmen | Position | Ende |
|---|---|---|
| COHERUS BIOSCIENCES, INC. | General Counsel | 01.10.2023 |
| PHATHOM PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 30.11.2019 |
ARTham Therapeutics, Inc.
 ARTham Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million. | Direktor/Vorstandsmitglied | - |
| Pharmacosmos Therapeutics Inc. | General Counsel | - |
| PROMETHEUS BIOSCIENCES, INC. | General Counsel | - |
Ausbildung von Chris Slavinsky
| Washington University School of Law | Graduate Degree |
| Thomas Jefferson University | Graduate Degree |
| Stony Brook University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Prometheus Biosciences, Inc.
 Prometheus Biosciences, Inc. BiotechnologyHealth Technology Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases. The company was founded by Scott Glenn and Stephan Targan on October 26, 2016 and is headquartered in San Diego, CA . | Health Technology |
| Pharmacosmos Therapeutics Inc. | |
ARTham Therapeutics, Inc.
ARTham Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million. | Health Technology |
